Evidence map›Paper›PMID 30807665›Full record

ArticleThe Prostate2019

PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens.

Susan Heavey, Helena Costa, Hayley Pye, Emma C Burt, Sophia Jenkinson, Georgina-Rose Lewis, Leticia Bosshard-Carter, Fran Watson, Charles Jameson, Marzena Ratynska and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Susan HeaveyMolecular Diagnostics and Therapeutics Group, University College London, London, UK.ORCID 0000-0002-2974-4578
Helena CostaResearch Department of Pathology, University College London, London, UK.
Hayley PyeMolecular Diagnostics and Therapeutics Group, University College London, London, UK.
Emma C BurtDepartment of Molecular Haematology, Barts Health NHS Trust, The Royal London Hospital, London, UK.
Sophia JenkinsonResearch Department of Pathology, University College London, London, UK.
Georgina-Rose LewisResearch Department of Pathology, University College London, London, UK.
Leticia Bosshard-CarterResearch Department of Pathology, University College London, London, UK.
Fran WatsonResearch Department of Pathology, University College London, London, UK.
Charles JamesonResearch Department of Pathology, University College London, London, UK.
Marzena RatynskaResearch Department of Pathology, University College London, London, UK.
Imen Ben-SalhaResearch Department of Pathology, University College London, London, UK.
Aiman HaiderResearch Department of Pathology, University College London, London, UK.
Edward W JohnstonCentre for Medical Imaging, University College London, London, UK.
Andrew FeberDivison of Surgery and Interventional Sciences, University College London, London, UK.
Greg ShawDepartment of Uro-Oncology, UCLH NHS Foundation Trust, London, UK.
Ashwin SridharDepartment of Uro-Oncology, UCLH NHS Foundation Trust, London, UK.
Senthil NathanDepartment of Uro-Oncology, UCLH NHS Foundation Trust, London, UK.
Prabhakar RajanDepartment of Uro-Oncology, UCLH NHS Foundation Trust, London, UK.
Timothy P BriggsDepartment of Uro-Oncology, UCLH NHS Foundation Trust, London, UK.
Prasanna SooriakumaranDepartment of Uro-Oncology, UCLH NHS Foundation Trust, London, UK.
John D KellyDepartment of Uro-Oncology, UCLH NHS Foundation Trust, London, UK.
Alex FreemanResearch Department of Pathology, University College London, London, UK.
Hayley C WhitakerMolecular Diagnostics and Therapeutics Group, University College London, London, UK.ORCID 0000-0002-2695-0202
University College London · GBUniversity College Hospital · GBIo Therapeutics (United States) · USBarts Health NHS Trust · GB

Funding

Department of Health Biomedical Research CentreProstate Cancer UK Centre of ExcellenceProstate Cancer UK PG14-018-TR2Prostate Cancer UK TLD-PF16-004
6 · The paper itself

Abstract

backgroundOver 1 million men are diagnosed with prostate cancer each year worldwide, with a wide range of research programs requiring access to patient tissue samples for development of improved diagnoses and treatments. A random sampling of prostate tissue is sufficient for certain research studies; however, there is growing research need to target areas of the aggressive tumor as fresh tissue. Here we set out to develop a new pathway "PEOPLE: PatiEnt prOstate samPLes for rEsearch" to collect high-quality fresh tissue for research use, using magnetic resonance imaging (MRI) to target areas of tumor and benign tissue.

methodsProstate tissue was sampled following robotic radical prostatectomy, using MRI data to target areas of benign and tumor tissue. Initially, 25 cases were sampled using MRI information from clinical notes. A further 59 cases were sampled using an optimized method that included specific MRI measurements of tumor location along with additional exclusion criteria. All cases were reviewed in batches with detailed clinical and histopathological data recorded. For one subset of samples, DNA was extracted and underwent quality control. Ex vivo culture was carried out using the gelatin sponge method for an additional subset.

resultsTumor was successfully fully or partially targeted in 64% of the initial cohort and 70% of the optimized cohort. DNA of high quality and concentration was isolated from 39 tumor samples, and ex vivo culture was successfully carried out in three cases with tissue morphology, proliferation, and apoptosis remaining comparable before and after 72 hours culture.

conclusionHere we report initial data from the PEOPLE pathway; using a method for targeting areas of tumor within prostate samples using MRI. This method operates alongside the standard clinical pathway and minimizes additional input from surgical, radiological, and pathological teams, while preserving surgical margins and diagnostic tissue.

Indexed as

Magnetic Resonance ImagingHumansMaleProstateProstatectomyProstatic NeoplasmsSpecimen Handlingbiobankcancermagnetic resonance imagingprostatesamplingspecimentissue

Identifiers

PMID30807665
PMCPMC6618051
OpenAlexW2917457893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.